Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). Methods This study included Part A: 10 healthy volunteers randomized to single oral doses of losmapimod (7.5 mg then 15 mg; n = 8) or placeb...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2021-12, Vol.87 (12), p.4658-4669
Main Authors: Mellion, Michelle L., Ronco, Lucienne, Berends, Cecile L., Pagan, Lisa, Brooks, Sander, Esdonk, Michiel J., Brummelen, Emilie M. J., Odueyungbo, Adefowope, Thompson, Lorin A., Hage, Michelle, Badrising, Umesh A., Raines, Shane, Tracewell, William G., Engelen, Baziel, Cadavid, Diego, Groeneveld, Geert J.
Format: Article
Language:English
Subjects:
Administration, Oral
Area Under Curve
Cyclopropanes - pharmacokinetics
Cyclopropanes - therapeutic use
facioscapulohumeral dystrophy
Humans
losmapimod
Muscular Dystrophy, Facioscapulohumeral - drug therapy
phase 1
Pyridines - pharmacokinetics
Pyridines - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Evaluate safety, tolerability, pharmacokinetics (PK) and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). Methods This study included Part A: 10 healthy volunteers randomized to single oral doses of losmapimod (7.5 mg then 15 mg; n = 8) or placebo (both periods; n = 2); Part B: 15 FSHD subjects randomized to placebo (n = 3), or losmapimod 7.5 mg (n = 6) or 15 mg (n = 6); and Part C: FSHD subjects received open‐label losmapimod 15 mg (n = 5) twice daily for 14 days. Biopsies were performed in FSHD subjects at baseline and Day 14 in magnetic resonance imaging‐normal appearing (Part B) and affected muscle identified by abnormal short‐tau inversion recovery sequence + (Part C). PK and TE, based on pHSP27:total HSP27, were assessed in muscle and sorbitol‐stimulated blood. Results PK profiles were similar between healthy volunteers and FSHD subjects, with mean Cmax and AUC0–12 for 15 mg in FSHD subjects (Part B) of 85.0 ± 16.7 ng*h/mL and 410 ± 50.3 ng*h/mL, respectively. Part B and Part C PK results were similar, and 7.5 mg results were approximately dose proportional to 15 mg results. Dose‐dependent concentrations in muscle (42.1 ± 10.5 ng/g [7.5 mg] to 97.2 ± 22.4 ng/g [15 mg]) were observed, with plasma‐to‐muscle ratio from ~0.67 to ~1 at estimated tmax of 3.5 hours postdose. TE was observed in blood and muscle. Adverse events (AEs) were mild and self‐limited. Conclusion Losmapimod was well tolerated, with no serious AEs. Dose‐dependent PK and TE were observed. This study supports advancing losmapimod into Phase 2 trials in FSHD. Clinical Trial Registration Clinical trial identifier ToetsingOnline: NL68539.056.18 Nederlands Trials Register NL8000.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.14884